Journal
CURRENT OPINION IN IMMUNOLOGY
Volume 52, Issue -, Pages 18-26Publisher
CURRENT BIOLOGY LTD
DOI: 10.1016/j.coi.2018.02.003
Keywords
-
Categories
Funding
- Deutsche Forschtmgsgemeinschaft [310/11]
- Deutsche Akademische Austauschdicnst
- European Cooperation in Science and Technology COST Action [BM1406 IONCHAN-IMMUNRESPON]
Ask authors/readers for more resources
Immune cells express various voltage-gated and ligand-gated ion channels that mediate the influx and efflux of charged ions across the plasma membrane, thereby controlling the membrane potential and mediating intracellular signal transduction pathways. These channels thus present potential targets for experimental modulation of immune responses and for therapeutic interventions in immune disease. Small molecule drugs and natural toxins acting on ion channels have illustrated the potential therapeutic benefit of targeting ion channels on immune cells. Unwanted side effects and immunogenicity have however hampered the application of these molecules. Owing to their high specificity, low immunogenicity and beneficial pharmacodynamics, antibodies targeting membrane and secretory proteins have emerged as potent therapeutics in oncology and inflammation. Nanobodies - single domain fragments derived from heavy chain antibodies naturally occurring in camelids - offer additional benefits versus antibodies, including protrusion into cryptic epitopes and easy formatting of multi-specific reagents. Here we review recent progress in the development and application of antibodies and Nanobodies targeting ion channels on immune cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available